View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Dashboards
  2. Filings
May 6, 2022

Filings buzz in pharmaceuticals: 25% decrease in cloud computing mentions in Q4 of 2021

We've analysed companies' annual reports and other filings to see which key issues are receiving the most attention.

By Data Journalism Team

Mentions of cloud computing within the filings of companies in the pharmaceutical industry fell 25% between the third and fourth quarters of 2021.

In total, the frequency of sentences related to cloud computing during 2021 was 109% higher than in 2016 when GlobalData, from whom our data for this article is taken, first began to track the key issues referred to in company filings.

When pharmaceutical companies publish annual and quarterly reports, ESG reports and other filings, GlobalData analyses the text and identifies individual sentences that relate to disruptive forces facing companies in the coming years. Cloud computing is one of these topics - companies that excel and invest in these areas are thought to be better prepared for the future business landscape and better equipped to survive unforeseen challenges.

To assess whether cloud computing is featuring more in the summaries and strategies of pharmaceutical companies, two measures were calculated. Firstly, we looked at the percentage of companies which have mentioned cloud computing at least once in filings during the past twelve months - this was 41% compared to 16% in 2016. Secondly, we calculated the percentage of total analysed sentences that referred to cloud computing.

Of the 40 biggest employers in the pharmaceutical industry, CSL was the company which referred to cloud computing the most during 2021. GlobalData identified nine cloud-related sentences in the Australia-based company's filings - 0.19% of all sentences. IQVIA mentioned cloud computing the second most - the issue was referred to in 0.15% of sentences in the company's filings. Other top employers with high cloud mentions included PRA, China Traditional and Takeda.

This analysis provides an approximate indication of which companies are focusing on cloud computing and how important the issue is considered within the pharmaceutical industry, but it also has limitations and should be interpreted carefully. For example, a company mentioning cloud computing more regularly is not necessarily proof that they are utilising new techniques or prioritising the issue, nor does it indicate whether the company's ventures into cloud computing have been successes or failures.

GlobalData also categorises cloud computing mentions by a series of subthemes. Of these subthemes, the most commonly referred to topic in the fourth quarter of 2021 was 'software as a service', which made up 60% of all cloud subtheme mentions by pharmaceutical companies.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena